Trials / Completed
CompletedNCT00716144
Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis
A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 176 (actual)
- Sponsor
- Stiefel, a GSK Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Talarozole | Oral Capsule Once Daily |
Timeline
- Start date
- 2006-06-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2008-07-16
- Last updated
- 2018-01-29
- Results posted
- 2018-01-29
Locations
22 sites across 5 countries: Germany, Ireland, Netherlands, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT00716144. Inclusion in this directory is not an endorsement.